Organogenesis is a drug manufacturers-specialty & generic business based in the US. Organogenesis shares (ORGO) are listed on the NASDAQ and all prices are listed in US Dollars. Organogenesis employs 950 staff and has a trailing 12-month revenue of around $463.9 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $2.80 |
|---|---|
| 52-week range | $2.23 - $9.27 |
| 50-day moving average | $2.64 |
| 200-day moving average | $4.16 |
| Wall St. target price | $11.00 |
| PE ratio | 6.1042 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.48 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.8 from 2023-02-03
| 1 week (2023-01-30) | 13.36% |
|---|---|
| 1 month (2023-01-06) | 6.06% |
| 3 months (2022-11-07) | -14.63% |
| 6 months (2022-08-05) | -54.77% |
| 1 year (2022-02-07) | -62.57% |
|---|---|
| 2 years (2021-02-05) | -78.44% |
| 3 years (2020-02-07) | 4.7 |
| 5 years (2018-02-06) | 10.05 |
Valuing Organogenesis stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Organogenesis's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Organogenesis's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, Organogenesis shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Organogenesis's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $53.4 million.
The EBITDA is a measure of a Organogenesis's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $463.9 million |
|---|---|
| Operating margin TTM | 9.14% |
| Gross profit TTM | $353.9 million |
| Return on assets TTM | 6.4% |
| Return on equity TTM | 26.82% |
| Profit margin | 12.88% |
| Book value | $1.96 |
| Market capitalisation | $383.6 million |
TTM: trailing 12 months
We're not expecting Organogenesis to pay a dividend over the next 12 months.
Over the last 12 months, Organogenesis's shares have ranged in value from as little as $2.23 up to $9.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Organogenesis's is 1.5011. This would suggest that Organogenesis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Organogenesis Holdings Inc. , a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.